Antioxidant dietary approach in treatment of fatty liver: New insights and updates
Non-alcoholic fatty liver disease (NAFLD) is a common clinicopathological condition, encompassing a range of conditions caused by lipid deposition within liver cells. To date, no approved drugs are available for the treatment of NAFLD, despite the fact that it represents a serious and growing clinic...
Uloženo v:
| Vydáno v: | World journal of gastroenterology : WJG Ročník 23; číslo 23; s. 4146 |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
21.06.2017
|
| Témata: | |
| ISSN: | 2219-2840, 2219-2840 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Non-alcoholic fatty liver disease (NAFLD) is a common clinicopathological condition, encompassing a range of conditions caused by lipid deposition within liver cells. To date, no approved drugs are available for the treatment of NAFLD, despite the fact that it represents a serious and growing clinical problem in the Western world. Identification of the molecular mechanisms leading to NAFLD-related fat accumulation, mitochondrial dysfunction and oxidative balance impairment facilitates the development of specific interventions aimed at preventing the progression of hepatic steatosis. In this review, we focus our attention on the role of dysfunctions in mitochondrial bioenergetics in the pathogenesis of fatty liver. Major data from the literature about the mitochondrial targeting of some antioxidant molecules as a potential treatment for hepatic steatosis are described and critically analysed. There is ample evidence of the positive effects of several classes of antioxidants, such as polyphenols (
., resveratrol, quercetin, coumestrol, anthocyanins, epigallocatechin gallate and curcumin), carotenoids (
., lycopene, astaxanthin and fucoxanthin) and glucosinolates (
., glucoraphanin, sulforaphane, sinigrin and allyl-isothiocyanate), on the reversion of fatty liver. Although the mechanism of action is not yet fully elucidated, in some cases an indirect interaction with mitochondrial metabolism is expected. We believe that such knowledge will eventually translate into the development of novel therapeutic approaches for fatty liver. |
|---|---|
| AbstractList | Non-alcoholic fatty liver disease (NAFLD) is a common clinicopathological condition, encompassing a range of conditions caused by lipid deposition within liver cells. To date, no approved drugs are available for the treatment of NAFLD, despite the fact that it represents a serious and growing clinical problem in the Western world. Identification of the molecular mechanisms leading to NAFLD-related fat accumulation, mitochondrial dysfunction and oxidative balance impairment facilitates the development of specific interventions aimed at preventing the progression of hepatic steatosis. In this review, we focus our attention on the role of dysfunctions in mitochondrial bioenergetics in the pathogenesis of fatty liver. Major data from the literature about the mitochondrial targeting of some antioxidant molecules as a potential treatment for hepatic steatosis are described and critically analysed. There is ample evidence of the positive effects of several classes of antioxidants, such as polyphenols (i.e., resveratrol, quercetin, coumestrol, anthocyanins, epigallocatechin gallate and curcumin), carotenoids (i.e., lycopene, astaxanthin and fucoxanthin) and glucosinolates (i.e., glucoraphanin, sulforaphane, sinigrin and allyl-isothiocyanate), on the reversion of fatty liver. Although the mechanism of action is not yet fully elucidated, in some cases an indirect interaction with mitochondrial metabolism is expected. We believe that such knowledge will eventually translate into the development of novel therapeutic approaches for fatty liver.Non-alcoholic fatty liver disease (NAFLD) is a common clinicopathological condition, encompassing a range of conditions caused by lipid deposition within liver cells. To date, no approved drugs are available for the treatment of NAFLD, despite the fact that it represents a serious and growing clinical problem in the Western world. Identification of the molecular mechanisms leading to NAFLD-related fat accumulation, mitochondrial dysfunction and oxidative balance impairment facilitates the development of specific interventions aimed at preventing the progression of hepatic steatosis. In this review, we focus our attention on the role of dysfunctions in mitochondrial bioenergetics in the pathogenesis of fatty liver. Major data from the literature about the mitochondrial targeting of some antioxidant molecules as a potential treatment for hepatic steatosis are described and critically analysed. There is ample evidence of the positive effects of several classes of antioxidants, such as polyphenols (i.e., resveratrol, quercetin, coumestrol, anthocyanins, epigallocatechin gallate and curcumin), carotenoids (i.e., lycopene, astaxanthin and fucoxanthin) and glucosinolates (i.e., glucoraphanin, sulforaphane, sinigrin and allyl-isothiocyanate), on the reversion of fatty liver. Although the mechanism of action is not yet fully elucidated, in some cases an indirect interaction with mitochondrial metabolism is expected. We believe that such knowledge will eventually translate into the development of novel therapeutic approaches for fatty liver. Non-alcoholic fatty liver disease (NAFLD) is a common clinicopathological condition, encompassing a range of conditions caused by lipid deposition within liver cells. To date, no approved drugs are available for the treatment of NAFLD, despite the fact that it represents a serious and growing clinical problem in the Western world. Identification of the molecular mechanisms leading to NAFLD-related fat accumulation, mitochondrial dysfunction and oxidative balance impairment facilitates the development of specific interventions aimed at preventing the progression of hepatic steatosis. In this review, we focus our attention on the role of dysfunctions in mitochondrial bioenergetics in the pathogenesis of fatty liver. Major data from the literature about the mitochondrial targeting of some antioxidant molecules as a potential treatment for hepatic steatosis are described and critically analysed. There is ample evidence of the positive effects of several classes of antioxidants, such as polyphenols ( ., resveratrol, quercetin, coumestrol, anthocyanins, epigallocatechin gallate and curcumin), carotenoids ( ., lycopene, astaxanthin and fucoxanthin) and glucosinolates ( ., glucoraphanin, sulforaphane, sinigrin and allyl-isothiocyanate), on the reversion of fatty liver. Although the mechanism of action is not yet fully elucidated, in some cases an indirect interaction with mitochondrial metabolism is expected. We believe that such knowledge will eventually translate into the development of novel therapeutic approaches for fatty liver. |
| Author | Ferramosca, Alessandra Di Giacomo, Mariangela Zara, Vincenzo |
| Author_xml | – sequence: 1 givenname: Alessandra surname: Ferramosca fullname: Ferramosca, Alessandra organization: Alessandra Ferramosca, Mariangela Di Giacomo, Vincenzo Zara, Dipartimento di Scienze e Tecnologie Biologiche ed Ambientali, Università del Salento, Via Provinciale Lecce-Monteroni, I-73100 Lecce, Italy – sequence: 2 givenname: Mariangela surname: Di Giacomo fullname: Di Giacomo, Mariangela organization: Alessandra Ferramosca, Mariangela Di Giacomo, Vincenzo Zara, Dipartimento di Scienze e Tecnologie Biologiche ed Ambientali, Università del Salento, Via Provinciale Lecce-Monteroni, I-73100 Lecce, Italy – sequence: 3 givenname: Vincenzo surname: Zara fullname: Zara, Vincenzo organization: Alessandra Ferramosca, Mariangela Di Giacomo, Vincenzo Zara, Dipartimento di Scienze e Tecnologie Biologiche ed Ambientali, Università del Salento, Via Provinciale Lecce-Monteroni, I-73100 Lecce, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28694655$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkM1LxDAQxYOsuB969yQ5emlN0yRNvS2LX7AoiJ7LtJnuZumXTbrr_vcWXMHD4w28H8PMm5NJ0zZIyHXEwjgR-u6w24R7Hod2lIiEOiMzzqM04Fqwyb95SubO7RjjcSz5BZlyrVKhpJyR92XjbfttDTSeGose-iOFrutbKLbUNtT3CL7GMW1LWoL3R1rZPfb39BUPI-DsZusdhcbQoTPg0V2S8xIqh1cnX5DPx4eP1XOwfnt6WS3XQSGZ8oFKSpXrQqWoODCN3OgShFJgmFQJxCWgSHiiOaCUkOscc53EjKnUoBA54wty-7t3PPZrQOez2roCqwoabAeXRWmUpCrikRjRmxM65DWarOttPT6a_fXAfwC-H2Kd |
| CitedBy_id | crossref_primary_10_1007_s00580_018_2834_y crossref_primary_10_1016_j_ijbiomac_2024_130988 crossref_primary_10_1016_j_matdes_2024_112825 crossref_primary_10_3390_md20040225 crossref_primary_10_1016_j_jhep_2022_03_034 crossref_primary_10_1016_j_bbadis_2018_07_012 crossref_primary_10_3390_medicina58121728 crossref_primary_10_31146_1682_8658_ecg_203_7_165_170 crossref_primary_10_1002_bab_2061 crossref_primary_10_1089_jmf_2019_4493 crossref_primary_10_1016_j_jff_2020_103781 crossref_primary_10_1159_000489166 crossref_primary_10_1016_j_phanu_2022_100290 crossref_primary_10_1016_j_heliyon_2024_e35498 crossref_primary_10_1039_D1FO03541J crossref_primary_10_1021_acs_molpharmaceut_5c00145 crossref_primary_10_1016_j_lfs_2023_121688 crossref_primary_10_3390_molecules27175568 crossref_primary_10_1111_eci_13020 crossref_primary_10_1186_s12864_021_07950_2 crossref_primary_10_3390_nu11123067 crossref_primary_10_4103_sjg_sjg_249_21 crossref_primary_10_1039_D1FO00290B crossref_primary_10_3390_genes13060936 crossref_primary_10_1111_jpn_13473 crossref_primary_10_3389_fnut_2023_1130224 crossref_primary_10_3390_antiox10020217 crossref_primary_10_3390_cimb47030159 crossref_primary_10_3389_fcvm_2024_1469492 crossref_primary_10_1186_s13550_018_0420_6 crossref_primary_10_3389_fphar_2020_00482 crossref_primary_10_1016_j_jnutbio_2019_03_006 crossref_primary_10_3390_nu13124484 crossref_primary_10_7717_peerj_9838 crossref_primary_10_3390_nu14091791 crossref_primary_10_4254_wjh_v13_i3_315 crossref_primary_10_1016_j_joim_2021_07_004 crossref_primary_10_3389_fphar_2021_680081 crossref_primary_10_1007_s00580_018_2853_8 crossref_primary_10_1007_s40200_021_00850_y crossref_primary_10_1007_s40200_022_01028_w crossref_primary_10_1016_j_jnutbio_2019_108296 crossref_primary_10_3390_cancers12040974 crossref_primary_10_3389_fendo_2020_00494 crossref_primary_10_1002_fsn3_2162 crossref_primary_10_5604_01_3001_0010_8630 crossref_primary_10_3390_ijms22105375 crossref_primary_10_1080_00365521_2022_2071109 crossref_primary_10_3389_fphar_2019_01693 crossref_primary_10_36290_med_2019_046 crossref_primary_10_3390_nu11122875 crossref_primary_10_3390_nu13061999 crossref_primary_10_1016_j_reprotox_2025_109043 crossref_primary_10_3390_livers3010002 crossref_primary_10_1016_j_biopha_2022_112820 crossref_primary_10_3390_foods12091780 crossref_primary_10_1016_j_phrs_2023_106925 crossref_primary_10_1186_s12967_023_04627_0 crossref_primary_10_1016_j_jep_2019_111919 crossref_primary_10_3390_ijms22147702 crossref_primary_10_3390_nu15061456 crossref_primary_10_3390_nu15245053 crossref_primary_10_3389_fcell_2021_745985 crossref_primary_10_3390_ijms23052542 crossref_primary_10_3390_antiox12081606 crossref_primary_10_1007_s00580_018_2854_7 crossref_primary_10_3390_antiox13091103 crossref_primary_10_1007_s13105_021_00850_9 crossref_primary_10_1038_s41538_025_00458_z crossref_primary_10_3389_fphar_2024_1406784 crossref_primary_10_12873_441bejarano crossref_primary_10_1016_j_bcp_2018_11_020 crossref_primary_10_1017_S0007114520002846 crossref_primary_10_3390_cimb46080531 crossref_primary_10_3390_nu17071214 crossref_primary_10_1016_j_ijpharm_2024_124381 crossref_primary_10_1016_j_fbio_2025_106935 crossref_primary_10_3390_biomedicines10020274 crossref_primary_10_3390_nu13030933 crossref_primary_10_3390_ani10040639 crossref_primary_10_1016_j_jep_2021_114873 crossref_primary_10_1016_j_biopha_2019_109083 crossref_primary_10_1016_j_clnesp_2020_10_020 crossref_primary_10_3390_nu15224755 crossref_primary_10_3748_wjg_v23_i43_7678 crossref_primary_10_1016_j_ceca_2020_102336 crossref_primary_10_1186_s12906_020_03076_2 crossref_primary_10_1016_j_fct_2021_112314 crossref_primary_10_1186_s13020_024_01011_y crossref_primary_10_1155_2024_5534697 crossref_primary_10_3389_fphar_2022_876550 crossref_primary_10_1080_13813455_2022_2102654 crossref_primary_10_1016_j_jep_2019_112129 crossref_primary_10_1016_j_lfs_2020_117990 crossref_primary_10_3390_ijms26167940 crossref_primary_10_1016_j_imr_2018_07_004 crossref_primary_10_1007_s11356_019_05059_4 crossref_primary_10_1007_s12562_019_01329_9 crossref_primary_10_1016_j_fbio_2025_107483 crossref_primary_10_4093_dmj_2021_0274 crossref_primary_10_1016_j_actbio_2023_09_030 crossref_primary_10_1016_j_clnesp_2025_02_008 crossref_primary_10_4103_ijpvm_IJPVM_411_20 crossref_primary_10_1111_1440_1681_12886 crossref_primary_10_3390_antiox13111384 crossref_primary_10_3389_fnut_2025_1473487 crossref_primary_10_3390_antiox8070229 crossref_primary_10_3390_nu14071331 crossref_primary_10_3390_nu10091137 crossref_primary_10_12998_wjcc_v11_i6_1236 crossref_primary_10_3390_nu14030541 crossref_primary_10_3390_biomedicines11020640 crossref_primary_10_1038_s41598_021_87367_9 crossref_primary_10_1038_s41598_024_63965_1 crossref_primary_10_1016_j_cbi_2020_109199 crossref_primary_10_1016_j_foodres_2018_11_004 crossref_primary_10_1016_j_jff_2018_01_003 crossref_primary_10_1016_j_jep_2020_112729 crossref_primary_10_3390_molecules26010006 crossref_primary_10_3390_antiox8080276 crossref_primary_10_1155_2021_6174897 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.3748/wjg.v23.i23.4146 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| EISSN | 2219-2840 |
| ExternalDocumentID | 28694655 |
| Genre | Journal Article Review |
| GroupedDBID | --- 123 29R 2WC 36B 53G 5VR 8WL AAKDD ACGFO AENEX AFUIB ALMA_UNASSIGNED_HOLDINGS CCEZO CGR CHBEP CIEJG CS3 CUY CVF CW9 DIK DU5 E3Z EBS ECM EIF EJD F5P FRP GX1 HYE NPM OK1 P2P RNS RPM TR2 XSB 7X8 |
| ID | FETCH-LOGICAL-c506t-67f6b8c69e62a08e2d8fa466ad0567a3fae472782ae55ab8beb8730069de44b02 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 135 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000403957600003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2219-2840 |
| IngestDate | Thu Oct 02 11:44:26 EDT 2025 Mon Jul 21 05:47:36 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 23 |
| Keywords | Oxidative stress Mitochondria Fatty liver Hepatic steatosis Lipogenesis |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c506t-67f6b8c69e62a08e2d8fa466ad0567a3fae472782ae55ab8beb8730069de44b02 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC5483489 |
| PMID | 28694655 |
| PQID | 1917961214 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1917961214 pubmed_primary_28694655 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-06-21 |
| PublicationDateYYYYMMDD | 2017-06-21 |
| PublicationDate_xml | – month: 06 year: 2017 text: 2017-06-21 day: 21 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | World journal of gastroenterology : WJG |
| PublicationTitleAlternate | World J Gastroenterol |
| PublicationYear | 2017 |
| SSID | ssj0023352 |
| Score | 2.5737114 |
| SecondaryResourceType | review_article |
| Snippet | Non-alcoholic fatty liver disease (NAFLD) is a common clinicopathological condition, encompassing a range of conditions caused by lipid deposition within liver... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 4146 |
| SubjectTerms | Animals Anthocyanins - pharmacology Antioxidants - pharmacology Carotenoids - pharmacology Catechin - analogs & derivatives Catechin - pharmacology Coumestrol - pharmacology Curcumin - pharmacology Energy Metabolism Fatty Liver - diet therapy Fatty Liver - metabolism Glucosinolates - pharmacology Humans Imidoesters - pharmacology Isothiocyanates - pharmacology Lipogenesis Mitochondria - metabolism Mitochondria - pathology Non-alcoholic Fatty Liver Disease - diet therapy Non-alcoholic Fatty Liver Disease - metabolism Nutritional Sciences Oxidative Stress Polyphenols - pharmacology Quercetin - pharmacology Resveratrol Stilbenes - pharmacology Xanthophylls - pharmacology |
| Title | Antioxidant dietary approach in treatment of fatty liver: New insights and updates |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28694655 https://www.proquest.com/docview/1917961214 |
| Volume | 23 |
| WOSCitedRecordID | wos000403957600003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7UevDiA1_1xQpet003m83GixRRPGgpotJb2WR3JSJJbdJq_70zaVpPguAhuSSBMJmd_WbmyzeEXDhfCecbyE504DFhfMMA1BumAZ0EDq5GFRnz5T7s9dRgEPXrgltR0yoXMbEK1CZPsEbexrwiQrkrcTX6YDg1Crur9QiNVdLwAcqgV4eDZReB4_9EOFwOViWDMOzN25QouNL-fHttTbnfSuEQFfz9DWBWG83t1n9fcZts1hCTduc-sUNWbLZLHrtIa_xKDViSmtSWejyjC0FxmmZ0yTinuaNOl-WMviNn45JCHIQbCsziC6ozQycjLBMUe-T59ubp-o7V8xRYEniyZDJ0MlaJjKzk8C0sN8ppIaU2gIJC7TttBcAZxbUNAh2r2MYK5exlZKwQscf3yVqWZ_aQUM-6MFaB5wDOCWUVZHHGiCiJhPaF6wRNcr4w0RD8FZsQOrP5pBj-GKlJDuZ2Ho7mwhpDrmSEem5Hf3j6mGxw3GE9yXjnhDQcrFZ7StaTaZkW47PKEeDc6z98A2Dnvd4 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antioxidant+dietary+approach+in+treatment+of+fatty+liver%3A+New+insights+and+updates&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Ferramosca%2C+Alessandra&rft.au=Di+Giacomo%2C+Mariangela&rft.au=Zara%2C+Vincenzo&rft.date=2017-06-21&rft.issn=2219-2840&rft.eissn=2219-2840&rft.volume=23&rft.issue=23&rft.spage=4146&rft_id=info:doi/10.3748%2Fwjg.v23.i23.4146&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2219-2840&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2219-2840&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2219-2840&client=summon |